21:10 , May 9, 2019 |  BioCentury  |  Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
20:04 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
23:56 , Jan 24, 2019 |  BC Extra  |  Preclinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
22:05 , Jun 1, 2018 |  BioCentury  |  Finance

Bacterial brain

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B. The round closed on May 31...
20:03 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Sequoia leads Cortexyme's $76M series B

Alzheimer’s disease company Cortexyme Inc. (South San Francisco, Calif.) raised $76 million in a series B round led by Sequoia Capital. Fellow new investors included Vulcan Capital, Verily Life Sciences LLC (South San Francisco, Calif.),...
12:02 , May 31, 2018 |  BC Extra  |  Financial News

Sequoia leads Cortexyme's $76M series B

Alzheimer’s disease company Cortexyme Inc. (South San Francisco, Calif.) raised $76 million in a series B round led by Sequoia Capital. Fellow new investors included Vulcan Capital, Verily Life Sciences LLC (South San Francisco, Calif.),...